24 min listen
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine
FromThe Bio Report
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine
FromThe Bio Report
ratings:
Length:
27 minutes
Released:
Sep 18, 2014
Format:
Podcast episode
Description
The U.S. Food and Drug Administration is moving to expand its regulatory domain by adding oversight of certain diagnostics it does not regulate today. The agency says thousands of these test are used daily to guide treatment decisions and diagnose disease, and it wants to ensure their validity and advance personalized medicine. We spoke to Nathan Beaver, a partner with Foley & Lardner, about the FDA’s efforts, the implications for diagnostics companies, and why the agency’s plans are being met with some resistance from industry and Congress.
Released:
Sep 18, 2014
Format:
Podcast episode
Titles in the series (100)
International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report